NCT03880357View on ClinicalTrials.gov

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

485

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Scalp Psoriasis
Interventions
DRUG

Betamethasone Scalp Suspension 0.064%;0.0005%

applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.

DRUG

Taclonex®

applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.

DRUG

Placebo topical suspension

applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.

Trial Locations (1)

28217

Catawba Research, LLC, Charlotte

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT03880357 - To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis | Biotech Hunter | Biotech Hunter